Publication details
Kombinační léčba hypertenze v roce 2012
| Title in English | Combination treatment for hypertension in the year 2012 |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; guidelines; combination treatment; fixed combination |
| Description | In the year 2007, new European guidelines on the diagnosis and treatment of hypertension were issued, followed by both Czech and British guidelines in 2008 and by the Reappraisal of European Guidelines in 2009. In 2011, new NICE (British) guidelines were released and new Czech Society of Hypertension guidelines are prepared in 2012. The individual guidelines are very similar, still some differences exist. The Czech Society of Hypertension has adopted the European classification with three prehypertension grades (optimal, normal, and high-normal blood pressure), three grades of hypertension, and isolated systolic hypertension as an independent entity. The management of hypertension mainly consists in achievement of normotension and use of combination treatment according to comorbid conditions. Good control of systolic blood pressure as well as control for additional risk parameters is essential. The most commonly recommended double combinations include a renin-angiotensin-aldosterone system (RAAS) blocker – an ACEI or a sartan plus a calcium blocker, followed by a renin-angiotensin-aldosterone system blocker plus a diuretic, and a calcium blocker plus a diuretic. Recently, a fixed combination of a calcium blocker plus a beta blocker has emerged. Recommended diuretics include primarily indapamide, secondly chlorthalidone; by contrast, hydrochlorothiazide is viewed critically. The main advantage of fixed combinations is increased patient compliance and, thus, better control of hypertension. We present an overview of fixed combinations of RAAS blockers plus calcium blockers registered in the Czech Republic as of May 2012. |